Australie - anglais - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - doxycycline hyclate, quantity: 58.15 mg (equivalent: doxycycline, qty 50 mg) - capsule, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; hypromellose phthalate; hypromellose; hyprolose; povidone; wheat starch; diethyl phthalate; purified water; gelatin; ethanol; shellac; pharmaceutical glaze; carbon black - doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. doxycycline is active against a wide range of gram-positive and gram-negative organisms. note: the 50 mg capsule is not a paediatric formulation. mayne pharma doxycycline capsules are indicated in the treatment of infections caused by the following micro-organisms: mycoplasma pneumoniae: primary atypical pneumonia. rickettsiae: queensland tick typhus, typhus fever and q fever. agents of psittacosis. calymmatobacterium (donovania) granulomitis: granuloma inguinale. agents of lymphogranuloma venereum. borreliae: relapsing fever. chlamydia trachomatis. mayne pharma doxycycline capsules are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline capsules alone, or in combination with topical agents. mayne pharma doxycycline is indicated in the treatment of infections caused by the following gram-negative micro-organisms: vibrio species: cholera. brucella species: brucellosis (in conjunction with streptomycin). yersinia pestis: plague. francisella tularensis: tularemia. bartonella bacilliformis: bartonellosis. bacteroides species. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum: syphilis. treponema pertenue: yaws. neisseria gonorrhoea: gonorrhoea (see dosage and administration). mayne pharma doxycycline capsules is not the drug of choice in the treatment of any type of staphylococcal infection or infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory tract infections due to group a beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. doxycycline is active against both pre-erythroycitic and asexual bloodstages of plasmodium falciparum. the tetracyclines are only partially active against the pre-erythrocytic stages of plasmodium vivax and protection depends on drug suppression of the blood stages. doxycycline has no activity against the relapsing forms (hypnozoites) of plasmodium vivax. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. in acute intestinal amoebiasis manye pharma doxycycline capsules may be a useful adjunct to amoebicides. in severe acne mayne pharma doxycycline capsules may be a useful adjunctive therapy

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxorubicin hydrochloride -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxorubicin hydrochloride -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - doxycycline -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxorubicin hydrochloride, quantity: 200 mg - injection - excipient ingredients: sodium chloride; dilute hydrochloric acid; water for injections - doxorubicin has been successfully used to produce regression in neoplastic conditions, eg acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma, etc. the main antitumour activities are listed in table 1. doxorubicin is also indicated in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2) by intravesical administration.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxorubicin hydrochloride, quantity: 100 mg - injection - excipient ingredients: water for injections; dilute hydrochloric acid; sodium chloride - doxorubicin has been successfully used to produce regression in neoplastic conditions, eg acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma, etc. the main antitumour activities are listed in table 1. doxorubicin is also indicated in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2) by intravesical administration.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxorubicin hydrochloride, quantity: 50 mg - injection - excipient ingredients: water for injections; dilute hydrochloric acid; sodium chloride - doxorubicin has been successfully used to produce regression in neoplastic conditions, eg acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma, etc. the main antitumour activities are listed in table 1. doxorubicin is also indicated in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2) by intravesical administration.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxorubicin hydrochloride, quantity: 10 mg - injection - excipient ingredients: sodium chloride; dilute hydrochloric acid; water for injections - doxorubicin has been successfully used to produce regression in neoplastic conditions, eg acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma, etc. the main antitumour activities are listed in table 1. doxorubicin is also indicated in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2) by intravesical administration.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - the fauldoxo has been used with success in the treatment of neoplasias, where it is capable of causing the regression of: acute leukaemia, wilm's tumor, neuroblastoma, sarcomas of the bone and soft tissues, carcinoma of the breast, lymphoma (hodgkin's and non-hodgkin's), bronchogenic carcinoma of the lung, carcinoma of the thyroid, carcinoma of the ovary and hepatomas.